Incidence of Clostridium difficile infection and antibiotics use in a third-level hospital

Misael Martínez Martínez; Andrés Flores Santos; Laura Cerda Ramos; Guadalupe Martínez Martínez; Fidel Martínez Gutiérrez

2017, Number 4

<< Back Next >>

Enf Infec Microbiol 2017; 37 (4)

**Incidence of Clostridium difficile infection and antibiotics use in a third-level hospital**

Martínez MM, Flores SA, Cerda RL, Martínez MG, Martínez GF

Full text

How to cite this article

Language: Spanish
References: 26
Page: 116-120
PDF size: 331.03 Kb.

ABSTRACT

Clostridium difficile (CD) is a Gram-positive, spore-forming, anaerobic, toxin-producing bacterium (A and B). Clostridium difficile infection (CDI) is one of the health care- associated infections (HCAI). People with weakened conditions have a higher risk of CDI, especially when they are in intensive care units for prolonged periods, keeping them exposed to circulating spores. Other risk factors are the indiscriminate use of antibiotics: mainly metronidazole and vancomycin.
Objective. to determine the prevalence of Clostridium difficile infections in patients treated at a tertiary level hospital: Central Hospital Dr. Ignacio Morones Prieto, San Luis Potosí, during 2015, the main hospital areas affected and their possible relationship with the use of antibiotics were determined.
Results. 44% of toxin tests were positive, of which 54.4% were positive for both toxins. The areas with the highest CDI incidence were Hospitalization (35%), Surgery (27%) and Intensive care units (22%), and the areas with greater use of metronidazole: Surgery and ICU, while for vancomycin, Hospitalization and Surgery.
Conclusions.the results suggest that there may be a relationship between intrahospital treatment with antibiotics and the development of CDI, due to the fact that antibiotics alter intestinal biota.

REFERENCES

Leffler, D.A. y Lamont, J.T., “Clostridium difficile infection”, N Eng J Med, 2015, 372 (16): 1539-1548.
Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A. et al., “Multistate point-prevalence survey of health care–associated infections”, N Eng J Med, 2014, 370 (13): 1198-1208.
DuPont, H.L., “The search for effective treatment of Clostridium difficile infection”, Mass Medical Soc, 2011.
O’Brien, J.A., Lahue, B.J., Caro, J.J. y Davidson, D.M., “The emerging infectious challenge of Clostridium difficile associated disease in Massachusetts hospitals: clinical and economic consequences”, Infect Control Hosp Epidemiol, 2007, 28 (11): 1219-1227.
“Centers for Disease Control and P. Vital signs: preventing Clostridium difficile infections”, mmwr, 2012, 61 (9): 157.
Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C. et al., “Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (shea) and the infectious diseases society of America (idsa)”, Infect Control Hosp Epidemiol, 2010, 31 (5): 431-455.
Kelly, C.P. y LaMont, J.T., “Clostridium difficile: more difficult than ever”, N Eng J Med, 2008, 359 (18): 1932-1940.
Bauer, M.P., Notermans, D.W., Van Benthem, B.H.B., Brazier, J.S., Wilcox, M.H., Rupnik, M. et al., “Clostridium difficile infection in Europe: a hospital-based survey”, Lancet, 2011, 377 (9759): 63-73.
Hernández-García, R., Garza-González, E., Miller, M., Arteaga- Muller, G., Galván-de los Santos, A.M. y Camacho-Ortiz, A., “Application of the atlas score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico”, Braz J Infect Dis, 2015, 19 (4): 399-402. Lopardo, G., Morfín-Otero, R., Morán-Vázquez, I.I.,
Noriega, F., Zambrano, B., Luxemburger, C. et al., “Epidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico”, Braz J Infect Dis, 2015, 19 (1): 8-14.
Thielman, N.M. y Wilson, K.H., “Antibiotic-associated colitis”, en Principles and practice of infectious diseases, Filadelfia, Churchill Livingstone, 2005, pp. 1249-1263.
Lessa, F.C., Gould, C.V. y McDonald, L.C., “Current status of Clostridium difficile infection epidemiology”, Clin Infect Dis, 2012, 55 (suppl 2): S65-S70.
Rupnik, M., “Is Clostridium difficile associated infection a potentially zoonotic and foodborne disease?”, Clin Microb Infect, 2007, 13 (5): 457-459.
Jangi, S. y Lamont, J.T., “Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life”, J Pediatr Gastroenterol Nutr, 2010, 51 (1): 2-7.
Rousseau, C., Poilane, I., De Pontual, L., Maherault, A.- C., Le Monnier, A. y Collignon, A., “Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains”, Clin Infect Dis, 2012, 55 (9): 1209-1215.
Labbé, A.-C., Poirier, L., MacCannell, D., Louie, T., Savoie, M., Béliveau, C. et al., “Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the bi/nap1/027 strain”, Antimicrob Agents Chemother, 2008, 52 (9): 3180-3187.
McDonald, L.C., Owings, M. y Jernigan, D.B., “Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003”, Emerg Infect Dis, 2006, 12 (3): 409.
Kuijper, E.J., Van Dissel, J.T. y Wilcox, M.H., “Clostridium difficile: changing epidemiology and new treatment options”, Curr Op Infect Dis, 2007, 20 (4): 376-383.
Camacho-Ortiz, A., Galindo-Fraga, A., Rancel-Cordero, A., Macías, A.E., Lamothe-Molina, P., De León-Garduño, A.P. et al., “Factores asociados con el desarrollo de la enfermedad por Clostridium difficile en un hospital de tercer nivel en México: estudio de casos y controles”, Rev Invest Clin, 2009, 61 (5): 371-377.
Zumbado-Salas, R., Del Mar Gamboa-Coronado, M., Rodríguez-Cavallini, E. y Chaves-Olarte, E., “Clostridium difficile in adult patients with nosocomial diarrhea in a Costa Rican hospital”, Am J Trop Med Hyg, 2008, 79 (2): 164-165.
Quesada-Gómez, C., López-Ureña, D., Acuña-Amador, L., Villalobos-Zúñiga, M., Du T. Freire, R. et al., “Emergence of an outbreak-associated Clostridium difficile variant with increased virulence”, J Clin Microbiol, 2015, 53 (4): 1216-1226.
Hernández-Rocha, C., Barra-Carrasco, J., Pizarro-Guajardo, M., Ibáñez, P., Bueno, S.M., Sarker, M.R. et al., “Epidemic Clostridium difficile ribotype 027 in Chile”, Emerg Infect Dis, 2012, 18 (8): 1370.
Pépin, J., Valiquette, L. y Cossette, B., “Mortality attributable to nosocomial Clostridium difficile associated disease during an epidemic caused by a hypervirulent strain in Quebec”, Canadian Medical Association Journal, 2005, 173 (9): 1037-1042.
Chitnis, A.S., Holzbauer, S.M., Belflower, R.M., Winston, L.G., Bamberg, W.M., Lyons, C. et al., “Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011”, jama Internal Medicine, 2013, 173 (14): 1359-1367.
Hempel, S., Newberry, S.J., Maher, A.R., Wang, Z., Miles, J.N.V., Shanman, R. et al., “Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis”, jama, 2012, 307 (18): 1959-1969.
Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C. et al., “Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (shea) and the infectious diseases society of America (idsa)”, Infection Control & Hospital Epidemiology, 2010, 31 (5): 431-455.